Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

On April 20, 2020 Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, reported that it will host a conference call and live audio webcast on Monday, April 27, at 8 a.m. EDT to discuss updated dose escalation safety and efficacy data from the company’s ongoing Phase I study of STRO-002 in ovarian and endometrial cancer that is being presented as a virtual poster at the AACR (Free AACR Whitepaper) Virtual Annual Meeting (Press release, Sutro Biopharma, APR 20, 2020, https://www.prnewswire.com/news-releases/sutro-biopharma-to-host-conference-call-on-april-27-2020-to-provide-clinical-update-on-its-stro-002-antibody-drug-conjugate-301043688.html [SID1234556441]). The virtual poster will be accompanied by a video presentation from Dr. Wendel Naumann of The Levine Cancer Institute.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

STRO-002 is a novel antibody-drug conjugate (ADC) targeting the clinically validated folate receptor-α (FolRα), an antigen known to be overexpressed in ovarian cancer. Sutro discovered, developed and manufactures STRO-002 using its proprietary XpressCF+ cell-free protein synthesis technology.

Conference Call Information:

To access the conference call and live audio webcast on Monday, April 27, at 8 a.m. EDT, please dial (833) 729-4781 (domestic) or (830) 213-7705 (international) and refer to conference ID 2699785.

The conference call will be webcast via the Investors page on the Company’s website at ir.sutrobio.com. Approximately two hours following the live event, a webcast replay of the conference call will be available through the Company Presentation page of the Investor section of the company’s website at www.sutrobio.com for approximately 30 days.

Poster Presentation Details:

STRO-002-GM1, a First in Human, Phase 1 Study of STRO-002, an anti-Folate Receptor-alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC), including Fallopian Tube or Primary Peritoneal Cancers

Date & Time:

Monday, April 27, 2020, 9:00 a.m. to 6:00 p.m. EDT

Location:

The AACR (Free AACR Whitepaper) Virtual Meeting at aacr.org

Poster Number:

CT125

The submitted abstract and the virtual poster presentation will also be accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company’s website at www.sutrobio.com on the day of the presentation.

McKesson Corporation to Announce Fourth Quarter Fiscal 2020 Results on May 20, 2020

On April 20, 2020 McKesson Corporation (NYSE:MCK) reported that it will release its fourth quarter fiscal 2020 financial results before market open on Wednesday, May 20, 2020 (Press release, McKesson, APR 20, 2020, View Source [SID1234556440]). The company will host a conference call for investors at 8:00 AM Eastern Time to review its financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the conference call will be available on McKesson’s Investor Relations website at View Source, along with the company’s earnings press release, financial tables and slide presentation. The conference call can also be accessed by dialing 786-815-8297. The password is ‘McKesson’.

Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I

On April 20, 2020 Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported the company will present a poster at the AACR (Free AACR Whitepaper) Virtual Annual Meeting I, taking place April 27-28, 2020 (Press release, Alpine Immune Sciences, APR 20, 2020, View Source [SID1234556439]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Presentation Title: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies
Session Title: VPO.CT07.01 – Phase I Trials in Progress
Date: Monday, April 27, 2020
Presentation Location: Virtual Meeting
Session Type: Virtual Poster Session
Poster Number: CT245
An abstract of the presentation will be available on the AACR (Free AACR Whitepaper) Virtual Annual Meeting I website.

About ALPN-202

ALPN-202 is a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor with the potential to improve upon the efficacy of combined checkpoint inhibition while limiting significant toxicities. Preclinical studies of ALPN-202 have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone. A phase 1 trial of ALPN-202 in advanced malignancies (NEON-1, NCT04186637) is open for enrollment.

TUKYSA™ (tucatinib) Approved for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer, Available from Onco360

On April 20, 2020 Onco360, the nation’s largest independent Oncology Pharmacy, reported that it has been selected by Seattle Genetics to be a specialty pharmacy partner for TUKYSA (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting (Press release, Onco360, APR 20, 2020, View Source [SID1234556438]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The approval of TUKYSA for patients with HER2-positive metastatic breast cancer is an important advancement in fighting this devastating disease," said Paul Jardina, President and CEO, Onco360. "As a specialty pharmacy dedicated to serving people with cancer, Onco360 is honored to be selected as a distribution partner for TUKYSA. We are committed to improving the lives of patients suffering from HER2-positive metastatic breast cancer."

According to the National Cancer Institute (NCI), approximately 276,480 patients are diagnosed with breast cancer annually, with corresponding 42,170 deaths. The five-year overall survival for breast cancer, regardless of stage, is 90%. Approximately 20% of breast cancer patients are found to be HER2-positive, an aggressive histological subtype of breast cancer. Unfortunately, about 25-30% of patients with HER2-positive breast cancer experience disease recurrence with metastatic disease.

TUKYSA is manufactured by Seattle Genetics, an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer. The FDA’s approval of TUKYSA in combination with capecitabine and trastuzumab is based on the results of the Phase II HER2CLIMB clinical trial, which demonstrated a 34% improvement in overall survival for the triplet regimen compared to capecitabine + trastuzumab doublet therapy. For full prescribing information, visit TUKYSA.com.

Community and hospital-based oncologists can immediately place prescription orders with Onco360 for TUKYSA, as well as other cancer and supportive care medications, including capecitabine and trastuzumab. Referral forms and information on how to order can be found at Onco360.com/Order.

Median Technologies Receives a Disbursement of €15 Million, Corresponding to the First Tranche of the Loan Granted by the European Investment Bank

On April 20, 2020 Median Technologies (Paris:ALMDT), The Imaging Phenomics Company reported that it had received the disbursement of €15 million, corresponding to the first tranche of the loan granted by the European Investment Bank (EIB) (Press release, MEDIAN Technologies, APR 20, 2020, View Source [SID1234556436]). The loan agreement was signed on December 18, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The loan agreement allows the Company to borrow up to €35 million. The second and third tranches, in the amount of €10 million each, may be drawn at the discretion of Median Technologies, subject to the achievement of a set of operational and financial performance criteria agreed upon with the EIB.

The objective of this financing, granted by the EIB together with the European Commission, under the guarantee of the European Fund for Strategic Investment (so called "Juncker Plan), is to support research and innovation projects developed by companies with substantial growth potential. Median Technologies meets these criteria as its iBiopsy technology has the potential to impact the lives of hundreds of thousands of patients worldwide.

iBiopsy fundamentals

Median develops imaging tests based on the most advanced AI technologies. Using imaging biomarkers, iBiopsy will identify in an innovative manner the specific signatures of certain diseases for their early detection, the quantification of their severity and their monitoring. The non-invasive imaging tests that the company is developing will help pharmaceutical companies develop new treatment for cancer and NASH patients. They will also provide key information to help patients receive treatment that is adapted to their specific conditions.

Outlook and main elements of the iBiopsy investment program for 2020

The funding granted by the EIB will cover the iBiopsy investment program over several years. For 2020, the iBiopsy roadmap focuses on several priorities: clinical development plan, product roadmap, key clinical and technological partnerships supported by a strategic intellectual property policy.

Clinical development and product roadmap: the clinical development plan will help channel the product deployment strategy in various areas of high clinical utility, such as:

A test for the non-invasive assessment of hepatic fibrosis (NASH), a disease whose prevalence is significantly increasing worldwide, as well as tests to assess treatment response in patients,
A test to identify potential responding patients to immuno-oncology treatment to enable biopharmaceutical companies better target the efficacy of their treatment during the phases of clinical tests and match the right treatment with the right patients in clinical routine,
A test for the detection, characterization and prognosis of HCC.
An assessment of commercial strategies for the reimbursement of tests and regulatory strategies in particular with the Food and Drug Administration (FDA) will also be carried out.

Strategic partnerships: like the collaboration agreement with AP-HP announced on March 2, 2020, Median Technologies will continue its partnership strategy with healthcare institutions and biopharmaceutical companies on a global scale, to ensure access to the best clinical expertise and high-quality imaging data. These partnerships, some of which are already being discussed, will be announced upon their signature. The partnership strategy will also cover agreements with technology companies, to enable the roll out of the iBiopsy platform by targeted sectors: healthcare institutions for clinical routine and biopharmaceutical companies for clinical research and development.

Intellectual property protection strategy: Median continues to develop its differentiating assets with the implementation at the end of 2019 of a strategy to pursue several patent submissions on iBiopsy. The innovations developed in 2019 are already the subject of several patents pending in Europe, the United States, China and Japan.

"This first disbursement of the loan granted to Median in December 2019, before the coronavirus crisis, proves the continuous support of the European Investment Bank to the Medtech sector and the health system in general", said Ambroise Fayolle, Vice-President of the EIB. "To cope with the health crisis that hits all Europe, EIB has decided to increase the financing of the health sector to €5 billion which will enable innovative companies like Median – pioneer in AI and health – to become a leading European company"

"This initial €15 million disbursement from the EIB allows us to strengthen our financial visibility and considerably step up our investment plan for iBiopsy", said Fredrik Brag, CEO and co-founder of Median Technologies. "Our current effort to solidify the clinical development plan will drive the iBiopsy product roadmap right through to regulatory filing which we expect to take place in 2021", he added.

As of the date on which this first loan disbursement is received from the EIB, Median Technologies intends to provide quarterly updates on iBiopsy, to ensure regularly updated information on its development to the Company’s various audiences.